Labcorp Q2 revenue $3.53B, Adj EPS $4.35; raises full-year guidance

LABCORP HOLDINGS INC.

2025-Q2 EPS reported $5.36 revenue$6,872,400,000

Q2 revenue $3.53B (+9.5% YoY); diluted EPS $2.84 vs $2.43; adjusted EPS $4.35 vs $3.94.
Full-year guidance raised: revenue growth 7.5%-8.6%; adjusted EPS $16.05-$16.50; FCF $1.13-$1.28B.
Diagnostics Labs revenue $2.75B (+8.9%); Biopharma Lab Services $784.8M (+11.0%).
Quarterly dividend $0.72/share declared; $200M stock repurchased in Q2.
Announced acquisitions of select assets from Incyte Diagnostics, BioReference Health, and Community Health Systems.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.